CDK Inhibitor p18INK4c Is Required for the Generation of Functional Plasma Cells  by Tourigny, Michelle R. et al.
Immunity, Vol. 17, 179–189, August, 2002, Copyright 2002 by Cell Press
CDK Inhibitor p18INK4c Is Required
for the Generation of Functional Plasma Cells
ory cells cycle infrequently, if at all. Although timely
cell cycle entry and exit is undoubtedly crucial for this
dynamic process, the precise mechanism is not known.
Michelle R. Tourigny,1,8 Josie Ursini-Siegel,1,8
Hayyoung Lee,1,8 Kai-Michael Toellner,3
Adam F. Cunningham,3 David S. Franklin,4
Scott Ely,1 Meihong Chen,1 The fact that plasma cells and memory cells are both
arrested in the G1 phase of the cell cycle further sug-Xiao-Feng Qin,5 Yue Xiong,6
Ian C.M. MacLennan,3 and Selina Chen-Kiang1,2,7 gests that cell cycle arrest may be a requisite for differ-
entiation of activated B cells to plasma cells or memory1Department of Pathology and
2 Department of Microbiology and Immunology cells, or both.
The mammalian cell cycle is regulated primarily by aWeill Medical College of Cornell University
1300 York Avenue family of serine/threonine protein kinases, consisting of
regulatory cyclin subunits and catalytic cyclin-depen-New York, New York 10021
3 University of Birmingham Medical School dent kinases (CDK) (Hunter and Pines, 1994). Two CDK
enzymes (CDK4 and CDK6) in combination with threeBirmingham
United Kingdom D-type cyclins (D1, D2, and D3), and CDK 2 in associa-
tion with cyclin E, play distinct and integral roles in4 Department of Biological Sciences
Purdue University regulating G1 progression (Weinberg, 1995). The CDK
activity is in turn negatively controlled by seven inhibi-West Lafayette, Indiana 47907
5 Laboratory of Molecular Immunology tors of the INK4 (p16INK4a, p15INK4b, p18INK4c, and p19INK4d)
and Cip/Kip (p21Cip1, p27Kip1, and p57Kip2) families (SherrThe Rockefeller University
New York, New York 10021 and Roberts, 1999). In vitro, INK4 family members spe-
cifically form inactive stable binary complexes with6 Department of Biochemistry and Biophysics
The University of North Carolina at Chapel Hill CDK4 and CDK6, whereas the CIP/KIP inhibitors have a
broader substrate specificity and inhibit kinase functionChapel Hill, North Carolina 27599
through the formation of ternary cyclin/CDK complexes
(Sherr and Roberts, 1999). Targeted gene disruption in
mice reveals a requirement for CDK inhibitors in someSummary
aspects of development (Sherr and Roberts, 1999), but
their physiological functions remain largely uncharac-B cell terminal differentiation is associated with the
onset of high-level antibody secretion and cell cycle terized.
Cell cycle control of B cell development and differenti-arrest. Here the cyclin-dependent kinase (CDK) inhibi-
tor p18INK4c is shown to be required within B cells for ation is a complex but poorly understood process. Sev-
eral CDK inhibitors (p19INK4d, p21Cip1, and p27Kip1), CDKs,both terminating cell proliferation and differentiation
of functional plasma cells. In its absence, B cells hy- and D-type cyclins have been shown to be regulated
by IL-4 and anti-IgM in primary mouse splenic B cellsperproliferate in germinal centers and extrafollicular
foci in response to T-dependent antigens but serum in vitro (Lam et al., 2000; Solvason et al., 1996; Tanguay
and Chiles, 1996). However, the relevance of these find-antibody titers are severely reduced, despite unim-
paired germinal center formation, class switch recom- ings to cell cycle control in B cell immunity has not been
defined. Previously, we demonstrated that inhibition ofbination, variable region-directed hypermutation, and
differentiation to antibody-containing plasmacytoid CDK6 by the CDK inhibitor p18INK4c (p18) (Guan et al.,
1994; Hirai et al., 1995) was coincidental with cell cyclecells. The novel link between cell cycle control and
plasma cell differentiation may, at least in part, relate arrest during terminal differentiation of human IgG
lymphoblastoid cells to plasma cells by IL-6 (Morse etto p18INK4c inhibition of CDK6. Cell cycle arrest medi-
ated by p18INK4C is therefore requisite for the genera- al., 1997). Moreover, the p18 level was increased in re-
sponse to IL-6, and forced expression of p18 was suffi-tion of functional plasma cells.
cient to cause G1 arrest of IgM lymphoblastoid cells by
Introduction inhibition of CDK6 (Morse et al., 1997). These results
suggest that p18 may play a critical role in terminating
The generation of a primary antibody response requires the cell cycle following B cell activation. Consistent with
activation and expansion of antigen-specific B cells by this possibility, we showed that mice deficient in p18
cell division, followed by terminal differentiation to anti- had increased numbers of B and T cells that displayed
body-secreting plasma cells (Jacob et al., 1991; Liu et elevated CDK6 activity (Franklin et al., 1998). The ab-
al., 1991; Smith et al., 1997). In successive immuniza- sence of p18 augmented the activation of resting B cells
tions, the antibody response is accelerated and ampli- and expansion in response to CD40L (Franklin et al.,
fied by the activation of long-lived, antigen-specific 1998) as well as the proliferation of primary lymphocytes
memory B cells (Ahmed and Gray, 1996). Plasma cells induced by PMA and concanavalin A in vitro (Latres et
are permanently withdrawn from the cell cycle and mem- al., 2000). These results suggest that through negative
cell cycle control, p18 participates in the regulation of
B cell immunity. It is not known whether B cell terminal7 Correspondence: sckiang@mail.med.cornell.edu
8 These authors contributed equally to this work. differentiation requires cell cycle arrest or, if it does,
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Figure 1. Impaired Primary NP-CGG Anti-
body Secretion Despite Normal Germinal
Center Formation in p18/ Mice
(A) ELISA of preimmune serum IgG and IgG
titers in 4-month-old p18/ (open circle) and
p18/ (filled circle) mice. The horizontal bars
represent mean values of eight mice.
(B) Serum NP-specific IgM (left) and IgG
(right) titers in p18/ and p18/ mice on indi-
cated days after immunization with NP-CGG.
The horizontal bars represent mean values of
four mice.
(C) and (D) Immunohistochemical analysis of
serial spleen sections showing germinal cen-
ters “G” and an extrafollicular focus of plas-
macytoid cells “E” from a p18/ mouse 6
days postimmunization. In (C), top panel
shows a switched germinal center and a few
IgM plasmacytoid cells. Lower panel indi-
cates the total number and area of germinal
centers in p18/ mice relative to p18/ mice
as deduced from histomorphometric analysis
of PNA and IgM stained sections. (D) Many
NP, IgG1-specific plasmacytoid cells are
seen in the top panel. Lower panel shows NP/
IgG (dark blue, vertical arrow), IgG (brown,
oblique arrow), and NP (light blue, horizontal
arrow)-specific plasmacytoid cells present in
an extrafollicular locus in a higher magnifi-
cation.
what role p18 plays in the plasma cell generation duced in the p18/ mice; the effect was particularly
marked in the switched antibody response (Figure 1B).process.
In this study, we demonstrate that p18-mediated cell The stage or stages in the primary response that were
affected by p18 deficiency were studied immunohisto-cycle arrest is essential for the final maturation of plas-
macytoid cells to functional, antibody-secreting plasma logically. Splenic B cells were shown to proliferate both
in follicles, where they formed germinal centers, and incells in the T-dependent humoral immune response.
This requirement is differentiation stage specific, be- extrafollicular foci as plasmacytoid cells (Figures 1C and
1D). These plasmacytoid cells contained NP- or CGG-cause p18 is dispensable for Ig switch recombination
and variable region hypermutation or differentiation of specific antibody and many had switched to IgG1 pro-
duction (Figure 1D). The p18-deficient mice generatedantigen-specific, switched B cells to plasmacytoid cells.
This provides direct evidence for the control of B cell more germinal centers than the control mice, as shown
by costaining for IgM and PNA (Figure 1C, lower panel;immunity by a specific cell cycle regulator.
data not shown), and the proportion of germinal center
B cells that had Ig switched confirmed that there wasResults
no defect in switch recombination (Figures 1C and 1D).
Thus, the impaired primary antibody response in theImpaired Antibody Secretion in the Absence of p18
p18/ mice cannot be attributed to defective germinalin a Primary T-Dependent Immune Response
center formation, Ig switch recombination, or plas-Enhanced expansion of activated B cells in the p18-
mablast formation. The data point to defective terminaldeficient mice (Franklin et al., 1998) suggests that they
differentiation of antibody-secreting plasma cells in themay develop autoimmunity, if p18 is dispensable for
absence of p18.terminal differentiation of activated B cells to antibody-
secreting plasma cells. However, a screen of serum im-
munoglobulin levels showed that both  and  antibody Defective Cell Cycle Arrest in p18-Deficient
Plasmacytoid Cellstiters were markedly reduced in unimmunized p18-defi-
cient mice compared with congenic wild-type mice (Fig- There were comparable numbers of total and NP-spe-
cific antibody-containing cells formed in splenic extra-ure 1A). This led us to test the requirement for p18 in
the T-dependent antibody response to (4-hydroxy-3- follicular foci of p18-deficient and control mice along
with similar numbers of switched NP-specific cells (Fig-nitrophenyl) acetyl linked to chicken -globulin (NP-
CGG) in p18-deficient mice. The serum NP-specific IgM ure 2A). To address the relationship between cell cycle
control and B cell terminal differentiation, we character-and IgG antibody levels increased with time after immu-
nization in the wild-type mice but lower titers were in- ized the expression of Ki67, which marks cycling cells,
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bility, since no NP-specific IgG-secreting plasma cells
were detected in the bone marrow by day 6 of reimmuni-
zation (Figure 3B, right). To further assess whether the
secretion defect is due to the absence of p18/ plas-
macytoid cells or failure of plasmacytoid cells to secrete
antibody in the bone marrow, the number of bone mar-
row IgM and IgG cells was enumerated during NP-CGG
responses (Figures 3C and 3D). IgM or IgG cells were
present in comparable numbers in the bone marrow of
p18-deficient and control mice in primary and secondary
immunizations, and more IgG cells were detected before
reimmunization (Figure 3C). Most of these cells were
plasmacytoid expressing a high level of intracellular Ig
(Figure 3D; data not shown). p18 is therefore dispens-
able for homing of plasmacytoid cells to the bone mar-
row but required for plasmacytoid cells to terminal differ-
entiate to Ig-secreting plasma cells as observed in the
spleen.
On reimmunization, comparable numbers of plas-
macytoid cells containing NP and CGG-specific anti-
body were again found in the splenic extrafollicular foci
in the p18/ and wild-type mice (Figure 4A). The early
onset and time course of expansion of NP-specific IgG
plasmacytoid cells indicates that the p18-deficient mice
were able, at the cellular level, to initiate a secondary
response (Figure 4A). However, a higher proportion of
the Syndecan-1-positive plasmacytoid cells in p18-defi-
cient mice were in cell cycle as indicated by Ki67 expres-Figure 2. Normal Ig Switching and Enhanced Replication in NP-
sion (Figure 4B), suggesting that they are defective inSpecific Extrafollicular Plasmacytoid Cells in p18/ Mice
cell cycle arrest as observed in the primary response.(A) The numbers of NP or NPIgG1 plasmacytoid cells per mm2
The absence of a secondary response in p18-deficientof spleen sections in p18/ and p18/ mice 6 days after immuni-
zation. mice is therefore due to defective cell cycle termination
(B) Percentage of NP-specific extrafollicular splenic plasmacytoid and antibody secretion of both splenic and bone marrow
cells expressing Ki67. plasmacytoid cells.
(C) Percentage of B220-positive splenic B cells that have taken
up BrdU in the 12 hr before the tissue was taken on days after
p18 Expression Is Increased in B Cellimmunization with NP-CGG. p18/ (open circle) and p18/ (filled
circle). Terminal Differentiation
The coordinated defects in cell cycle arrest and Ig secre-
tion suggest that p18 mediates a critical link between
in extrafollicular plasmacytoid cells. This revealed that cell cycle termination and final differentiation of plas-
at least twice as many NP-positive p18/ cells were macytoid cells to Ig-secreting plasma cells. Further-
cycling, suggesting that p18 is required for efficient cell more, p18 may be regulated during plasma cell differen-
cycle arrest of extrafollicular antibody-containing cells tiation as observed in IL-6 differentiation of human IgG
during the primary response (Figure 2B). Corroborating plasma cells in vitro (Morse et al., 1997). The p18 protein
this result, twice as many B220 splenic B cells from level was extremely low in both resting or activated
p18/ mice had taken up 5-bromo-2-deoxyuridine splenic B cells before immunization and increased in
(BrdU) within the 12 hr prior to the removal of spleen on splenic B cells by day 3 of reimmunization (Figure 4D),
days 4 and 11 after immunization (Figure 2C). p18 is coincidental with the expansion of NP-specific IgG plas-
therefore required for efficient cell cycle arrest of B cells macytoid cells and the onset of Ig secretion (Figures 4A
and plasmacytoid cells in vivo. and 3B). p18 expression is therefore increased during
B cell terminal differentiation in vivo.
BLIMP-1 is thought to be important for the commit-The Secondary Response Is Virtually Absent
in p18/ Mice ment of B cell terminal differentiation (Piskurich et al.,
2000). The expression of Syndecan-1, a target of BLIMPOn reimmunization, the defect in the antibody response
was even more pronounced in p18/ mice. The serum regulation (Turner et al., 1994) on p18/ plasmacytoid
cells, (Figure 4B) predicts that the BLIMP-1 expression isantibody titers of either NP or CGG were virtually absent
(Figure 3A), and the frequency of NP-IgG-secreting cells not contingent on p18. This was confirmed; the BLIMP-1
RNA levels were significantly higher in Syndecan-1 posi-in the spleen, as determined by ELISPOT, was drastically
reduced (Figure 3B, left). Thus, the secondary NP-CGG tive plasmacytoid cells compared to Syndecan-1 nega-
tive B cells on day 6 of reimmunization, regardless of theresponse is virtually absent in p18/ mice.
The absence of serum antibody titers suggests that presence of p18 (Figure 4E). p18 may therefore function
downstream or complementary to BLIMP-1. In eitherantibody secretion must also be defective in bone mar-
row plasmacytoid cells. ELISPOT confirmed this possi- case, p18 is increased during plasma cell differentiation
Immunity
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Figure 3. Severe Reduction of Serum Antibody Titers and Antibody-Secreting Plasma Cells in Secondary NP-CGG Response in p18/ Mice
(A) ELISA of serum NP (left)- and CGG-specific (right) IgG titers.
(B) ELISPOT of the number of plasma cells secreting NP-specific IgG (AFC) per 106 splenic B cells (left) and total bone marrow cells (right) in
p18/ (open circle) and p18/ (filled circle) mice on indicated days after reimmunization. The horizontal bars are mean values of 8 mice in
the ELISA and 4–6 mice in the ELISPOT analyses.
(C) The percentage of IgM (open bar) and the percentage of p18/ (open bar) and p18/ (filled bar) IgM and IgG cells present in the bone
marrow during and between primary and secondary immunization on day 42 (indicated as “O”). Each bar represents the mean of three mice.
The result is representative of three experiments.
(D) Plasmacytoid cells containing high levels of IgM revealed by immunofluoresene staining. The arrows indicate the corresponding cell by
DAPI staining.
and required for both cell cycle termination and final from p18/ mice (Figure 5A) and six from wild-type
differentiation to Ig-secreting plasma cells. controls (data not shown). The V region sequences from
the p18/ mice show extensive mutation with evidence
of serial acquisition of mutations. The pattern of muta-p18 Deficiency Does Not Impair Hypermutation
tions is comparable to those published previously (Ja-in Germinal Centers but Enhances
cob et al., 1993; Weiss et al., 1992), including the high-Plasmacytoid Cell Apoptosis
affinity tryptophan to leucine mutation at codon 33. p18These data link impaired cell cycle arrest to defective
deficiency therefore has no effect on the induction ofmaturation of plasmacytoid cells to antibody-secreting
Ig-directed hypermutation in germinal centers.plasma cells in p18/ mice in both primary and second-
A closer inspection of the NP-specific IgG-containingary responses. The time course of expansion of NP-
plasmacytoid cells in the extrafollicular foci of p18/specific plasmacytoid cells (Figure 4A) further suggests
mice indicates that although the time course of theirthat p18 deficiency is unlikely to affect V region hyper-
expansion is similar to the wild-type mice, there weremutation in germinal centers. To confirm this possibility,
fewer numbers of cells at each time point (Figure 4A).cells were scraped from an NP-specific germinal center
The increased proliferation of these antibody-containingidentified in sections of spleens taken from mice on day
cells (Figure 4B) without a corresponding increase in14 of the primary response to NP-CGG. The Ig variable
cell number (Figure 4A) implies a higher death rate inregion DNA was amplified by RT-PCR, cloned, and se-
quenced. Twelve independent sequences were isolated p18/ plasmacytoid cells. This was confirmed by
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Figure 4. Enhanced p18 Expression in Plas-
macytoid Cells and Hyperproliferation of NP-
Specific Plasmacytoid Cells upon Reimmuni-
zation in p18-Deficient Mice
(A) The number of NP-, NP-, and IgG-specific
extrafollicular plasmacytoid cells per mm2 of
spleen sections of p18/ (open) and p18/
(filled) mice on indicated days after reimmuni-
zation. Horizontal bars are the mean values
of each time point.
(B) Immunohistochemical analysis of splenic
extrafollicular plasmacytoid cells expressing
Ki67 (brown) and Syndecan-1 (red) in p18/
and p18/ mice on day 2 after reimmuni-
zation.
(C) The percentage of KI67-positive cells
among Syndecan-1 positive cells.
(D) Immunoblot analysis of p18 protein pres-
ent in total cell lysates (80 g) prepared from
resting (H) and activated (L) splenic B cells
of preimmune p18/ mice, and splenic B
cells of p18/ and p18/ mice on day 3 after
reimmunization. The blot was reprobed with
an actin antibody as a control for protein
loading.
(E) RT-PCR analysis for BLIMP-1 and actin
RNA levels in Syndecan-1-positive and -neg-
ative splenic B cells isolated from p18/ and
p18/ mice on day 6 after reimmunization.
TUNEL staining of IgG-containing plasmacytoid cells on p18 Is Required within B Cells for Negative Cell
Cycle Control and Ig Secretion during B Cellday 2 after reimmunization (Figures 5B and 5C). Thus,
while B cells are not prone to apoptosis in the absence Terminal Differentiation
Consistent with an essential role in the T-dependentof p18 in vitro (Franklin et al., 1998), p18-deficient plas-
macytoid cells, which fail to differentiate to antibody- response, p18 is required for negative control of splenic
B cell expansion mediated by CD40 in vitro (Franklin etsecreting plasma cells, are more rapidly eliminated by
apoptosis in splenic extrafollicular foci. al., 1998). Whether p18 is required within B cells to cou-
Figure 5. Unimpaired Ig V Region Hypermutation and Enhanced Plasmacytoid Cell Apoptosis in p18/ Mice
(A) The evolution of four clones from a germinal center isolated from the spleen of a p18/ mouse on day 14 after primary NP-CGG immunization.
Each clone was identified by its common CDR3 sequences; the V and D segment origins of clones are shown in the four top circles. The
numbers in the other circles are the arbitrary sequence number prefixed with an “S.” Circles with no numbers are deduced intermediate
members of the clone that were not isolated. Numbers beside the arrows of each tree indicate the codons in which mutations are found.
Codon numbers are assigned according to Kabat et al. (1991). The tree on the left is based on the canonical V186.2-DFL16.2-Jh2 combination
found in C57BL/6 mice in responses to NP (Cumano and Rajewsky, 1985; Weiss et al., 1992). This clone developed the typical high-affinity
mutation in codon 33 (squared). The sequence data have been submitted to GenBank/EMBL/DDBJ under accession numbers AJ427323–
AJ427334.
(B) TUNEL (brown) analysis of IgG (red) cells on day 2 of secondary response in spleen sections prepared from p18/ and p18/ mice
(400, insert at 1000).
(C) The histogram represents the average percentage of TUNEL cells among the IgG cells per spleen on day 2 after secondary immunization.
The bars represent the values derived from counting 250 IgG cells over four individual sections. Results from individual animals are represented
by open (p18/) or closed bars (p18/).
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Figure 6. p18 Is Required within B Cells for Negative Cell Cycle Control and Ig Secretion but Not for Ig Switch Recombination during Terminal
Differentiation
(A) Expansion of viable p18/ (open circle) and p18/ (filled circle) cells on days of in vitro differentiation of resting splenic B cells by CD40L,
IL-4, IL-6, and Ox40.
(B) Flow cytometric analysis of BrDU uptake by p18/ (upper) or p18/ (lower) B cells on day 8 of in vitro differentiation.
(C) Flow cytometric analysis of p18/ (top panel) and p18/ (lower panel) B cells expressing high levels of intracellular IgG1 on day 13 of in
vitro differentiation.
(D) ELISA of Ig secreted into the media by p18/ (open circle) or p18/ (filled circle) B cells on indicated days of in vitro differentiation.
The values represent cumulative IgG titers of the preceding 3 days, including the day shown (days 0–3, days 5–8, and days 8–11). The results
of two representative experiments are shown.
ple cell cycle control to Ig secretion was addressed by p18/ splenic B cells induced by CD40L alone was due
terminal differentiation of primary B cells in vitro (Figure to an increase in S phase cells (Figure 7A). Analysis of
6). Primary plasma cells were generated in vitro by co- CDK inhibitor expression by immunoblotting following
culturing resting splenic B cells, recovered from the 60- saturating immunoprecipitation indicated sustained ex-
70% interface of a discontinuous Percoll gradient, with pression of p18 and the closely related p19INK4d (Chan
mitomycin C-arrested CD40L-expressing L cells at a et al., 1995; Guan et al., 1996; Hirai et al., 1995) during
10:1 ratio (Do et al., 2000). The majority of cells (85%) cell cycle activation (S) and the subsequent onset of G1
entered the cell cycle by day 3 as determined by BrdU cell cycle arrest (Figure 7B). By contrast, while both
uptake and continued to proliferate until the onset of p21Cip1 and p27Kip1 were abundantly present in resting
G1 arrest around day 6. The addition of IL-6, IL-4, and B cells, p21 was progressively and markedly reduced
OX40 prolonged cell expansion, induced efficient Ig during cell cycle entry and arrest, thus unlikely to play
switch recombination and terminal differentiation to Ig- a key role in mediating cell cycle arrest during B cell
secreting plasma cells by day 8 (Figures 6A–6D). terminal differentiation. The p27 expression diminished
It is evident that p18 is required to negatively control in response to CD40L but was restored in G1-arrested
the aggregated cell cycle signals mediated by CD40 cells to a level approaching that of resting B cells. Thus,
and cytokines, because twice as many live p18/ cells CDK inhibitors are differentially regulated in primary B
accumulated by day 13 (Figure 6A). This was due to cells in CD40 signaling, and despite their expression
enhanced cell replication in the absence of p18, as indi- in G1 arrested cells, p19 and p27 cannot functionally
cated by the enhanced BrdU uptake within 2 hr on day compensate for the loss of p18 in B cells.
8 (21.1% versus 11.53%) (Figure 6B). As predicted from p18 preferentially inhibits CDK6 activity in cultured
the NP-CGG response in vivo, the absence of p18 does myogenic cells and primary T cells in vitro (Franklin and
not affect Ig switch recombination since comparable Xiong, 1996; Kovalev et al., 2001). CDK6 was regulated
fractions of p18/ and p18/ plasmacytoid cells (58% by CD40 independent of p18, being barely detectable
versus 52%) express a high level of intracellular IgG1 in resting B cells, prominently elevated in activated B
by day 13 (Figure 6C). However, IgG secretion was pro- cells, and slightly reduced in G1-arrested cells (Figure
foundly impaired in the absence of p18, 2-fold by day 7C). By contrast, CDK4 was highly expressed in resting
8 and 3-fold by day 11 (Figure 6D). p18 is therefore B cells and only marginally regulated by CD40 (Figure
required within B cells for both negative cell cycle con- 7C). Immunoblots of p18 immune complexes show that
trol and efficient Ig secretion, but not for Ig switch re- p18 binds a substantial and constant amount of both
combination. CDKs in cycling and G1-arrested B cells (Figure 7D).
Analysis of p18- and p19-associated CDK4 and CDK6
on the same blot indicate that p18 preferentially bindsp18 Inhibits CD40-Signaled Cell Cycle Progression
CDK6 while p19 binds both CDKs comparably (Figureby Preferential Inhibition of CDK6
7D). CDK4 and CDK6 are therefore differentially regu-To address the biochemical mechanism of p18 action
in B cells, we first confirmed that hyperproliferation of lated by CD40L, and p18 is likely to attenuate CD40-
Control of Plasma Cell Differentiation by p18
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Figure 7. Differential Regulation of CDK Inhibitors and CDKs by CD40L
(A) Upper panel shows the expansion of viable p18/ (open circle) and p18/ (filled circle) cells, and lower panel shows the percentage of
S phase cells on days of in vitro differentiation of resting splenic B cells by CD40L alone.
(B) Immunoblotting analysis of p18, p19, p21, and p27 in immunoprecipitates of resting splenic B cells without activation (G1, -), CD40L-
activated cycling B cells (S, ), and cells entering G1 arrest following activation (G1, ).
(C) Immunoblots of CDK6 and CDK4 expression in the same cells shown as in (B).
(D) Immunoblots of CDK6 and CDK4 levels present in the p18 and p19 immune complexes shown in (B).
(E) Analysis of CDK6 and CDK4 catalytic activities in resting, CD40-activated, and G1 arrested cells. The fold kinase activity represents the
ratio of CDK activity in p18/ cells relative to that in p18/ cells, after subtraction of nonspecific GST-Rb phosphorylation activity revealed
in the presence of blocking peptides.
mediated cell cycle progression primarily through inhibi- (Figure 1) and is virtually absent in the secondary re-
sponse due to defective secretion in both spleen andtion of CDK6.
To test this, the CDK activities were determined by bone marrow (Figure 3). Increased replication of extra-
follicular plasmacytoid cells (Figures 2 and 4) in the con-assaying phosphorylation of RB by the CDK immune
complexes (Figure 7E). The CDK6 activity correlates text of normal germinal center formation (Figure 1), Ig
switch recombination, and V region hypermutation (Fig-tightly with the protein levels: undetectable in resting B
cells, elevated in cycling B cells, and reduced in G1- ures 1–6) suggests that p18 is specifically required for
plasmacytoid cells to terminate the cell cycle and differ-arrested cells. CDK4 was already detected in resting
B cells and showed modest changes. Importantly, the entiate into Ig-secreting plasma cells. This requirement
is intrinsic to B cells, because the defects in cell controlabsence of p18 led to a 3-fold increase in the CDK6
activity in cycling B cells and a 1.6-fold increase in CDK4 arrest and IgG secretion are recapitulated during termi-
nal differentiation of p18-deficient B cells by CD40 andactivity in the same cells (Figure 7E). Given the prominent
regulation of CDK6 by CD40L (Figure 7C), these results cytokines in vitro (Figures 6 and 7). Together with the
essential role of p18 in negative control of TCR-mediatedsupport that p18 inhibits CD40-signaled cell cycle pro-
gression by preferential inhibition of CDK6. T cell proliferation (Kovalev et al., 2001), this study pro-
vides direct evidence that a cell cycle regulator controls
the T-dependent humoral immune response, affectingDiscussion
both B and T lineage cells, and suggests an underlying
biochemical mechanism.Plasma cell differentiation is a multistep process that is
not well understood. In this study, we have demon-
strated a requirement of the CDK inhibitor p18 for the p18 Is Required within B Cells for Cell Cycle Arrest
and Differentiation to Ig-Secreting Plasma Cellsgeneration of functional, antibody-secreting plasma
cells. In its absence, antibody secretion is notably re- p18 controls B cell terminal differentiation by mediating
a critical link between cell cycle control and generationduced during, and even before, primary immunization
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of functional plasma cells: plasmacytoid cells express- for B cell terminal differentiation, BLIMP-1 and XBP-1.
BLIMP was identified as a zinc finger-containing tran-ing abundant antigen-specific intracellular IgM and IgG
are present as replicating, nonsecreting intermediates scription factor capable of inducing IgM secretion and
Syndecan-1 expression when ectopically expressed inin the extrafollicular foci and bone marrow of p18/
mice (Figures 3 and 4). These p18/ plasmacytoid cells mature B cell lines (Turner et al., 1994). It has been
postulated to promote the commitment of plasma cellare otherwise indistinguishable from Ig-secreting plasma
cells based on the expression of known plasma cell differentiation based on its ability to activate or repress
multiple genes that are expressed or extinct in plasmasurface markers such as Syndecan-1 and the loss of
others such as B220 (Figure 4B; M.R.T. and S.C.-K., cells in vitro (Piskurich et al., 2000). However, BLIMP-1
expression is not restricted to B lineage cells (Changunpublished data).
Contrasting its requirement in cell cycle control, the et al., 2000), and its essential role in B cell terminal
differentiation remains to be confirmed by gene tar-absence of p18 does not affect the survival of CD40L-
activated B cells in vitro (Franklin et al., 1998). However, geting studies. Clearly, p18 is not required for the ex-
pression of BLIMP-1 in B cells or its activation in Synde-inappropriately cycling p18/ plasmacytoid cells are
more rapidly eliminated by apoptosis in the splenic ex- can-1-positive plasmacytoid cells during the NP-CGG
response (Figure 4E). Nonetheless, it is possible thattrafollicular foci early during the secondary NP-CGG re-
sponse (Figures 5, 4C, and 4D). The severe defect in through transcriptional regulation and cell cycle control,
BLIMP and p18 may function in concert in the commit-antibody secretion (compare Figures 3 and 1) implies
that extrinsic factors uniquely present in the secondary ment and final maturation of functional plasma cells at
two distinct stages of B cell terminal differentiation.response may augment cell cycle progression, thereby
increasing the need for p18 to maintain negative cell The absence of XBP-1, a basic leucine zipper-con-
taining transcription factor (Liou et al., 1990), results incycle control. While the signals that control cell cycle-
directed homeostasis of plasmacytoid cells in the extra- defective plasma cell generation and antibody produc-
tion, but germinal centers form in reconstituted RAG2-follicular foci are unknown, our data suggest a model
in which p18-mediated cell cycle arrest induces differen- deficient mice (Reimold et al., 2001). Independent inves-
tigations of the unfolded protein response have furthertiation of plasmacytoid cells to Ig-secreting plasma cells
within a restricted time, and failure to do so leads to revealed that GRP78 (Bip) (Haas and Wabl, 1983), a
stress-induced endoplasmic reticulum chaperone pro-their removal by apoptosis. This model is consistent
with the modulation of plasmablast survival by extrinsic tein (Lee, 2001; Lee et al., 1981), is regulated by XBP-1
in model cell line systems in vitro (Calfon et al., 2002;constraints as we have previously proposed (Sze et al.,
2000). Yoshida et al., 2001). GRP78, along with related ER
stress-induced proteins, have been shown to facilitateThe requirement for p18 in Ig secretion is not limited
to splenic plasmacytoid cells, given the severe defect in the assembly of nascent Ig heavy and light chains
in the endoplasmic reticulum (Melnick et al., 1994).Ig secretion by bone marrow IgM and IgG plasmacytoid
cells in p18/ mice (Figures 4B–4D). Thus, while p18 is Whether the p18 defects relate to impaired functions of
XBP-1 and GRPs poses an exciting question that re-dispensable for homing of plasmacytoid cells to bone
marrow and their survival in the bone marrow microenvi- mains to be addressed.
ronment, it is required for terminal differentiation to func-
tional plasma cells. Thus, the requirement for p18 in The Specificity and Biochemical Mechanism
the differentiation of plasmacytoid cells to Ig-secreting of p18 Action in B Cells
plasma cells is extraordinarily specific and independent p18 is expressed in many tissues (Guan et al., 1994) but
of their microenvironment. is dispensable for development, including the B and T
lineages (Franklin et al., 1998). We now show that p18
is required specifically for the final step of B cell terminalp18 Is a Physiologic Regulator of B Cell
Terminal Differentiation differentiation in the T-dependent antibody response.
This requirement is specific among CDK inhibitors sinceLittle is known about gene regulation in primary plasma
cells. However, the p18 protein level is elevated in Syn- the p18 deficiency cannot be functionally compensated
by another CDK inhibitor in vivo, not even its closestdecan-1-positive plasmacytoid cells in the secondary
NP-CGG response (Figure 4D), while remaining constant relative p19, which has a similar expression pattern in
B cells (Figure 7B).in response to CD40 in vitro (Figure 7B). Given the in-
crease in p18 protein during terminal differentiation of Biochemical dissection of p18 action in B cells in vitro
has confirmed that p18 is required within B cells tohuman IgG plasma cells by IL-6 (Morse et al., 1997), IL-6
is likely to be one physiologic signal that regulates p18 counter CD40-mediated cell cycle progression (Figure
7) and that hyperproliferation of p18/ B cells is notexpression in the humoral immune response. IL-6 is
known to be essential for IgG and IgA antibody secretion secondary to elevated CD40 expression (H.L. and
S.C.-K., unpublished data). This requirement for p18 isin vivo (Kopf et al., 1994; Ramsay et al., 1994) and func-
tions as a potent survival factor for B cells and plasma specific, given that resting splenic B cells isolated from
mice lacking p16INK4a, p21CIP1, or p27KIP1 do not hyperproli-cells (J.U.-S. and S.C.-K., unpublished data). p18 may
therefore integrate IL-6 signals to facilitate cell cycle ferate under the same conditions in vitro (H.L. and
S.C.-K., unpublished data). The p18 requirement may intermination, as well as plasma cell differentiation and
survival in vivo. part be due to differential regulation of CDK inhibitors
and CDKs by CD40L and IL-6 and preferential interactionThis raises the question of the relationship between
p18 and two transcription factors that are important between p18 and CDK6. p18 is regulated by IL-6 but
Control of Plasma Cell Differentiation by p18
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ELISA and ELISPOTnot CD40L whereas CDK6 is prominently regulated by
ELISA was carried out as previously described (Do et al., 2000) toCD40L but not IL-6 (Figures 4 and 7; Morse et al., 1997).
determine the total serum  and  titers in 4-month-old unimmunizedIn response to CD40L alone, p18 attenuate G1 progres-
mice, the relative NP- and CGG-specific serum Ig titers after immuni-
sion of primary B cells by binding and inhibiting a con- zation with NP-CGG, and IgG secreted into the media during in vitro
stant amount of CDK6, and less CDK4, thereby limiting terminal differentiation of primary B cells. The only modification was
that wells were coated with 1 g of CGG (Sigma) or 2.5 g of athe availability of free CDK6. During a physiologic NP-
goat-anti mouse  or  antibody (Southern Biotech). Detection ofCGG response in vivo, p18 levels are elevated presum-
plasma cells secreting NP- or CGG-specific IgG by ELISPOT wasably by IL-6 (Figure 4C), leading to more efficient inhibi-
performed also as described (Do et al., 2000), using low-densitytion of CDK6 and G1 arrest. The absence of p18 would
splenic B cells isolated on indicated days after immunization or
then lower the threshold for CDK6 activation and permit bone marrow cells flushed from the femur and tibia of mice on day
cell cycle progression. 6 after secondary immunization with NP-CGG.
This hypothesis does not exclude the cooperation
between p18 and other CDK inhibitors expressed in B In Vivo and In Vitro BrdU Labeling and Detection
For in vivo bromodeoxyuridine (BrdU) labeling studies, mice werecells, because CD40L-activated B cells eventually enter
injected intraperitoneally with 2.5 mg BrdU in 200 l PBS at theG1 arrest despite the residual CDK6 activity, and the
indicated times after immunization and sacrificed 12 hr later. Low-presence of CDK4 activity alone in resting B cells is
density splenic B cells were cytospun onto slides and stained withinsufficient to initiate cell cycle entry (Figure 7E). The
a FITC-conjugated anti-BrdU mouse monoclonal antibody (Boeh-
augmented germinal center formation in p18/ mice in ringer Mannheim) and a rhodamine-conjugated anti-B220 antibody
the primary NP-CGG response (Figure 1) may result from (PharMingen) (Morse et al., 1997). The cells were counterstained
with DAPI (Boehringer Mannheim); the number of BrdU-positive cellsboth increased availability of CD40L as a consequence
is expressed as a percentage of B220-positive cells. Cells wereof enhanced T cell expansion (H.L. and S.C.-K., unpub-
counted in triplicate from each mouse; at least 500 cells werelished data) and lack of negative cell cycle control by
counted in each sampling.p18 in B cells. It is unknown whether p18 is required for
Analysis of BrdU uptake in vitro was carried out as previously
negative cell cycle control in a T-independent immune described (Do et al., 2000), with the exception that propidium iodide
response. If so, p18 would negatively control cell cycle was not added to the final samples. In brief, cells were incubated
with BrDU in regular RPMI media (5 g/ml) for 2 hr during in vitrosignals mediated by distinct physiologic signals for a
differentiation, washed twice in phenol red-free RPMI containingsuccessful antibody response. The way cell cycle con-
5% fetal calf serum, and fixed overnight in 70% ethanol at 4C. Aftertrol relates to the onset of efficient Ig secretion poses
centrifugation, cells were resuspended in 2 N HCl-0.5% Triton-X-a fascinating challenge to future research.
100 and incubated for 30 min at room temperature, neutralized with
0.1 M Tetraborate (pH 8.5), and rinsed twice in RPMI containing 5%
Experimental Procedures fetal calf serum serum and 0.5% Tween-20. The cells were stained
with the above-mentioned anti-BrdU antibody and analyzed by flow
Immunization and Isolation of B Cells cytometry.
p18/ and p18/ mice (Franklin et al., 1998) (8- to 14-week-old,
age-matched) were immunized intraperitoneally with 75 g alum- Immunohistochemistry and Immunoflourescence Staining
precipitated NP-CGG (21:1; Biosearch Technologies, Inc.) (Toellner Immunohistochemical detection of intracellular antibodies specific
et al., 1996). Five to six weeks later, secondary responses were for NP, or the expression of IgG1, IgM, IgD, or the proliferation
elicited by injecting tail veins with 15 g NP-CGG in PBS. The num- marker Ki67 (Starborg et al., 1996) in splenic cells was carried out
ber of mice used in each time point during the primary and secondary on cryosections (5 m) and enumerated as previously described
responses is as indicated. High-density (resting B cells) and low- (Luther et al., 1997; Sze et al., 2000). The proportion of NP-positive
density (activated B cells and plasma cells) cells were isolated from extrafollicular cells expressing Ki67 shown in Figure 2 was deter-
the 60%–70% and 50%–60% interface, respectively, of a discontinu- mined by counting 500 NP positive cells, or as many as were on
ous Percoll gradient as previously described (Do et al., 2000). the section.
Detection of proliferating and apoptotic plasmacytoid cells shown
in Figures 4 and 5 was carried out on 5 m sections of formalinTerminal Differentiation of Primary IgG-Secreting
Plasma Cells In Vitro fixed, paraffin-embedded spleens. For simultaneous detection of
Syndecan-1 and Ki67, the sections were stained first with anti-Ki67Resting splenic B cells were isolated and differentiated in vitro by
coculturing with mitomycin-C arrested mouse CD40L-expressing L (Becton Dickinson, San Jose, CA) using an immunoperoxidase de-
tection system (Ventana Medical Systems, Inc., Tuscon, AZ) andcells essentially as previously described (Do et al., 2000). In some
cultures, baculovirus-produced recombinant human IL-6 (40 U/ml) then with an anti-mouse Syndecan-1 antibody (Pharmingen) using
a ChemMate alkaline phosphatase detection system (Ventana, Tuc-(Morse et al., 1997) and the soluble human gp80 subunit of the
IL-6 receptor, which enhances IL-6 signaling, were added from the son, AZ). Cells were then counterstained with methyl green (Aldrich,
Mikwaukee, WI). TUNEL-positive cells were detected using thebeginning. Recombinant mouse IL-4 (200 U/mL, a gift from Cindy
Watson and Bill Paul) and OX40-Ig (1:30 dilution) (Stuber et al., 1995) ApopTag kit (Intergen, Purchase, NY) according to the manufactur-
er’s specifications. The sections were then stained with anti-mousewere added from day 4 onward to promote Ig switch recombination,
cell survival, and terminal differentiation. Determination of viable IgG (Vector, Burlingame, CA, Cat#BA-9200) and counterstained with
methyl green. The number of Syndecan-1 positive cells that werecells by trypan blue exclusion and the percentage of S phase cells
by flow cytometry were carried out as described (Do et al., 2000). Ki67-positive (Figures 4B and 4C) and intracellular IgG-positive cells
that were TUNEL-positive (Figures 5B and 5C) were counted, 500To detect intracellular IgG by flow cytometry, the in vitro differenti-
ated B cells and plasma cells were collected, rinsed twice in phenol cells in each counting, from four different regions of the extrafollicu-
lar foci of each spleen using an eight channel Diffcount (Modulusred-free RPMI, and fixed in 4% paraformaldehyde for 5 min at 37C.
They were then rinsed twice again with PBS containing 0.1% BSA, Data Systems, Santa Clara, CA).
To detect IgM and IgG cells in the bone marrow, total bone marrowpermeabilized in a PBS buffer containing 10 mM Hepes, 0.1% BSA,
and 0.1% saponin (Sigma), and stained with an FITC-conjugated cells were collected by flushing the femurs of mice with RPMI at
indicated days after primary NP-CGG immunization, or reimmuniza-anti-mouse IgG1 antibody (Pharmingen) for 30 min on ice. After two
rinses in the permeabilization buffer, cells were analyzed by flow tion day 42 later. The cells were cytospun onto slides, stained with
rhodamine-anti-mouse IgM and FITC-anti-mouse IgG, and countercytometry using a FACS Calibur (Becton Dickinson) and CellQuest
software. stained with DAPI. The IgM- or IgG-positive cells present at each
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time point in each mouse were counted three times, 500 cells per a SCOR grant from the Leukemia and Lymphoma Society of America
to S.C-K.sampling. Three to five mice were used for each time point.
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